Download PDF
Fortschr Neurol Psychiatr 2004; 72(10): 586-591
DOI: 10.1055/s-2004-830049
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Atomoxetin in der Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Kindern und Erwachsenen

Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity DisorderE.  Davids1 , M.  Gastpar1
  • 1Klinik für Psychiatrie und Psychotherapie der Universität Duisburg-Essen (Direktor: Prof. Dr. med. M. Gastpar), Rheinische Kliniken Essen
Die vorliegende Arbeit unterliegt keiner Industrieförderung
Further Information

Publication History

Publication Date:
27 September 2004 (online)

    Permissions and Reprints

Zusammenfassung

Atomoxetin ist ein selektiver Noradrenalin-Wiederaufnahmehemmer, dessen Wirksamkeit bei Kindern, Jugendlichen und Erwachsenen mit einer Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) geprüft wurde. Bisher wurden 2 offene und 7 randomisierte, doppel-blinde, plazebo-kontrollierte klinische Untersuchungen zu Atomoxetin bei ADHS durchgeführt, davon 6 bei Kindern und Jugendlichen sowie 3 bei Erwachsenen. Jede dieser Untersuchungen zeigte eine Wirksamkeit von Atomoxetin bei ADHS, zumeist dokumentiert anhand der primären Zielkriterien ADHD Rating Scale (ADHD RS) und Conners Adult ADHD Rating Scale (CAARS). Atomoxetin wurde von den Patienten mit ADHS in der Regel gut toleriert. Die häufigste Nebenwirkung war verminderter Appetit. In den USA wurde Atomoxetin im November 2002 für die Behandlung von Kindern, Jugendlichen und Erwachsenen mit ADHS zugelassen. Im deutschsprachigen Raum ist Atomoxetin in dieser Indikation bisher nicht zugelassen, es kann daher bisher lediglich in der off-label-Verschreibung angewendet werden.

Abstract

Atomoxetine is a selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention-deficit/hyperactivity disorder (ADHD). In vitro, ex vivo and in vivo studies have shown that atomoxetine is a highly selective antagonist of the presynaptic norepinephrine transporter with little or no affinity for other noradrenergic receptors or other neurotransmitter transporters or receptors. So far, two open-label and seven randomised, double-blind, placebo-controlled, clinical trials have been published, six in youths and three in adults. Each of these trials has shown a positive response as measured by the primary efficacy measures, the ADHD-IV Rating Scale (ADHD RS) or the Conners Adult ADHD Rating Scale (CAARS). Atomoxetine has generally been well tolerated. The most common treatment-related adverse event was decreased appetite. Atomoxetine shows no abuse potential and is not a controlled substance in the US. In November of 2002 the FDA approved atomoxetine for use in the US for the treatment of ADHD in children, adolescents and adults. Atomoxetine is the first nonstimulant approved by the FDA for the treatment of ADHD and the first medication approved for the treatment of adult ADHD.

Literatur

  • 1 Barkley R A. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD.  Psychol Bull. 1997;  121 65-94
    CrossrefPubMedGoogle Scholar
  • 2 Castellanos F X. Toward a pathophysiology of attention-deficit/hyperactivity disorder.  Clin Pediatr. 1997;  36 381-393
    PubMedGoogle Scholar
  • 3 Internationale Klassifikation psychischer Störungen, ICD-10, Kapitel V (F), Weltgesundheitsorganisation. Göttingen: Verlag Hans Huber 1991
    Google Scholar
  • 4 Amercian Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders, 4th edit. Washington, DC 1994
    Google Scholar
  • 5 Barkley R A, Fischer M, Edelbrock C S, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study.  J Am Acad Child Adolesc Psychiatry. 1990;  29 546-557
    CrossrefPubMedGoogle Scholar
  • 6 Gallagher R, Blader J. The diagnosis and neuropsychological assessment of adult attention deficit/hyperactivity disorder.  Ann N Y Acad Sci. 2001;  931 148-171
    PubMedGoogle Scholar
  • 7 Groß J, Blocher D, Trott G E, Rösler M. Erfassung des hyperkinetischen Syndroms bei Erwachsenen.  Nervenarzt. 1999;  70 20-25
    CrossrefPubMedGoogle Scholar
  • 8 Krause K H, Krause J, Trott G E. Das hyperkinetische Syndrom (Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung) des Erwachsenenalters.  Nervenarzt. 1998;  69 543-556
    CrossrefPubMedGoogle Scholar
  • 9 Blocher D, Henkel K, Retz W, Retz-Junginger P, Thome J, Rösler M. Symptome aus dem Spektrum des hyperkinetischen Synrdoms bei Sexualdelinquenten.  Fortschr Neurol Psychiat. 2001;  69 453-459
    PubMedGoogle Scholar
  • 10 Faraone S V, Biederman J. Neurobiology of attention-deficit hyperactivity disorder.  Biol Psychiatry. 1998;  44 951-958
    CrossrefPubMedGoogle Scholar
  • 11 FDA . Strattera approved to treat ADHD.  FDA Consum. 2003;  37 4
    PubMedGoogle Scholar
  • 12 Fritze J, Schmauss M. [Off-label use: the case of methylphenidate (Ritalin)].  Nervenarzt. 2002;  73 1210-1212
    PubMedGoogle Scholar
  • 13 Preti A. Tomoxetine.  Curr Opin Investig Drugs. 2002;  3 272-277
    PubMedGoogle Scholar
  • 14 Zerbe R L, Rowe H, Enas G G, Wong D, Farid N, Lemberger L. Clinical pharmacology of tomoxetine, a potential antidepressant.  J Pharmacol Exp Ther. 1985;  232 139-143
    PubMedGoogle Scholar
  • 15 Barr C L, Kroft J, Feng Y, Wigg K, Roberts W, Malone M, Ickowicz A, Schachar R, Tannock R, Kennedy J L. The norepinephrine transporter gene and attention-deficit hyperactivity disorder.  Am J Med Genet. 2002;  114 255-259
    CrossrefPubMedGoogle Scholar
  • 16 Biederman J, Spencer T. Attention-deficit/hyperactivity disorder as a noradrenergic disorder.  Biol Psychiatry. 1999;  46 1234-1242
    CrossrefPubMedGoogle Scholar
  • 17 Spencer T J, Biederman J, Wilens T E, Faraone S V. Overview and neurobiology of attention-deficit/hyperactivity disorder.  J Clin Psychiatry. 2002;  63 Suppl 12 3-9
    PubMedGoogle Scholar
  • 18 Kratochvil C J, Vaughan B S, Harrington M J, Burke W J. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder.  Expert Opin Pharmacother. 2003;  4 1165-1174
    CrossrefPubMedGoogle Scholar
  • 19 Simpson D, Perry C M. Atomoxetine.  Paediatr Drugs. 2003;  5 407-415
    PubMedGoogle Scholar
  • 20 Stahl S M. Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition.  J Clin Psychiatry. 2003;  64 110-111
    PubMedGoogle Scholar
  • 21 Gehlert D R, Gackenheimer S L, Robertson D W. Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites.  Neurosci. Lett ;  157 203-206
    PubMedGoogle Scholar
  • 22 Bymaster F P, Katner J S, Nelson D L, Hemrick-Luecke S K, Threlkeld P G, Heiligenstein J H, Morin S M, Gehlert D R, Perry K W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention-deficit/hyperactivity disorder.  Neuropsychopharmacology. 2002;  27 699-711
    CrossrefPubMedGoogle Scholar
  • 23 Garces K. Atomoxetine for attention deficit/hyperactivity disorder.  Issues Emerg Health Technol. 2003;  46 1-4
    PubMedGoogle Scholar
  • 24 Ring B J, Gillespie J S, Eckstein J A, Wrighton S A. Identification of the human cytochromes P450 responsible for atomoxetine metabolism.  Drug Metab Dispos. 2002;  30 319-323
    CrossrefPubMedGoogle Scholar
  • 25 Sauer J M, Ponsler G D, Mattiuz E L, Long A J, Witcher J W, Thomasson H R, Desante K A. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism.  Drug Metab Dispos. 2003;  31 98-107
    CrossrefPubMedGoogle Scholar
  • 26 Belle D J, Ernest C S, Sauer J M, Smith B P, Thomasson H R, Witcher J W. Effect of potent CYD2D6 inhibition by paroxetine on atomoxetine pharmacokinetics.  J Clin Pharmacol. 2002;  42 1219-1227
    CrossrefPubMedGoogle Scholar
  • 27 Farid N A, Bergstrom R F, Ziege E A, Parli C J, Lemberger L. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects.  J Clin Pharmacol. 1985;  25 296-301
    PubMedGoogle Scholar
  • 28 Witcher J W, Long A, Smith B, Sauer J M, Heiligenstein J, Wilens T, Spencer T, Biederman J. Atomoxetine pharmacokinetics in children and adolescents with attention-deficit hyperactivity disorder.  J Child Adolesc Psychopharmacol. 2003;  13 53-63
    PubMedGoogle Scholar
  • 29 Chalon S A, Desager J P, Desante K A, Frye R F, Witcher J, Long A J, Sauer J M, Golnez J L, Smith B P, Thomasson H R, Horsmans Y. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.  Clin Pharmacol Ther. 2003;  73 178-191
    CrossrefPubMedGoogle Scholar
  • 30 Wernicke J, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J. Cardiovascular effects of atomoxetine in children, adolescents, and adults.  Drug Saf. 2003;  26 729-740
    PubMedGoogle Scholar
  • 31 Wernicke J F, Kratochvil C J. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.  J Clin Psychiatry. 2002;  63 Suppl 12 50-55
    PubMedGoogle Scholar
  • 32 Biederman J, Baldessarini R J, Wright V, Knee D, Harmatz J S. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy.  J Am Acad Child Adolesc Psychiatry. 1989;  28 777-784
    CrossrefPubMedGoogle Scholar
  • 33 Otka J E, Mercadante M T, Scahill L, Leckman J F. Reboxetine as a potentially effective treatment for attention defcit hyperactivity disorder.  J Child Adolesc Psychopharmacol. 2001;  11 203-204
    CrossrefPubMedGoogle Scholar
  • 34 Pliszka S R. Non-stimulant treatment of attention-deficit/hyperactivity disorder.  CNS Spectr. 2003;  8 253-258
    PubMedGoogle Scholar
  • 35 Popper C W. Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder.  Child Adolesc Psychiatr Clin N Am. 2000;  9 605-646
    PubMedGoogle Scholar
  • 36 Schweitzer J B, Holcomb H H. Drugs under investigation for attention-deficit hyperactivity disorder.  Curr Opin Investig Drugs. 2002;  3 1207-1211
    PubMedGoogle Scholar
  • 37 Spencer T J, Biederman J. Non-stimulant treatment for Attention-Deficit/Hyperactivity Disorder.  J Atten Disord. 2002;  6 S109-119
    PubMedGoogle Scholar
  • 38 Spencer T, Biederman J, Coffey B, Geller D, Crawford M, Bearman S K, Tarazi R, Faraone S V. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder.  Arch Gen Psychiatry. 2002;  59 649-656
    PubMedGoogle Scholar
  • 39 Spencer T J, Biederman J, Wilens T E, Faraone S V. Novel treatments for attention-deficit/hyperactivity disorder in children.  J Clin Psychiatry. 2002;  63 Suppl 12 16-22
    PubMedGoogle Scholar
  • 40 Spencer T J, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone S V, Seidman L. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.  Am J Psychiatry. 1998;  155 693-695
    PubMedGoogle Scholar
  • 41 Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone S V, Rea J, Witcher J, Zervas S. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder.  J Child Adolesc Psychopharmacol. 2001;  11 251-265
    CrossrefPubMedGoogle Scholar
  • 42 Kratochvil C J, Heiligenstein J H, Dittmann R, Spencer T J, Biederman J, Wernicke J, Newcorn J H, Casat C, Milton D, Michelson D. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.  J Am Acad Child Adolesc Psychiatry. 2002;  41 776-784
    PubMedGoogle Scholar
  • 43 Spencer T, Heiligenstein J H, Biederman J, Faries D E, Kratochvil C J, Conners C K, Potter W Z. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.  J Clin Psychiatry. 2002;  63 1140-1147
    PubMedGoogle Scholar
  • 44 Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee F R, Spencer T. , Atomoxetine ADHD Study Group . Atomoxetine in the treatment of children and adolescents with attention deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.  Pediatrics. 2001;  108 e83
    CrossrefPubMedGoogle Scholar
  • 45 Michelson D, Allen A J, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee F R, Sangal R B, Saylor K, West S, Kelsey D, Wernicke J, Trapp N J, Harder D. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.  Am J Psychiatry. 2002;  159 1896-1901
    CrossrefPubMedGoogle Scholar
  • 46 Bukstein O G. Once-daily atomoxetine may reduce attention deficit hyperactivity disorder in children and adolescents.  Evid Based Ment Health. 2003;  6 42
    PubMedGoogle Scholar
  • 47 Michelson D, Adler L, Spencer T, Reimherr F W, West S A, Allen A J, Kelsey D, Wernicke J, Dietrich A, Milton D. Atomoxetine in adults with ADHD: two randomized placebo-controlled studies.  Biol Psychiatry. 2003;  53 112-120
    CrossrefPubMedGoogle Scholar
  • 48 Heinzl S. Atomoxetin für Kinder und Erwachsene mit ADHS.  Psychopharmakotherapie. 2003;  10 120-124
    PubMedGoogle Scholar
  • 49 Heil S H, Holmes H W, Bickel W K, Higgins S T, Badger G J, Laws H F, Faries D E. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users.  Drug Alcohol Depend. 2002;  67 149-156
    CrossrefPubMedGoogle Scholar

Priv.-Doz. Dr. med. Eugen Davids

Klinik für Psychiatrie und Psychotherapie der Universität Duisburg-Essen · Rheinische Kliniken Essen

Virchowstraße 174

45147 Essen

Email: eugen.davids@uni-essen.de

      >